FI951155A0 - Farmaseuttinen valmiste - Google Patents

Farmaseuttinen valmiste

Info

Publication number
FI951155A0
FI951155A0 FI951155A FI951155A FI951155A0 FI 951155 A0 FI951155 A0 FI 951155A0 FI 951155 A FI951155 A FI 951155A FI 951155 A FI951155 A FI 951155A FI 951155 A0 FI951155 A0 FI 951155A0
Authority
FI
Finland
Prior art keywords
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
FI951155A
Other languages
English (en)
Swedish (sv)
Other versions
FI951155A (fi
Inventor
Ronald Brown Miller
Stewart Thomas Leslie
Derek Allan Prater
Trevor John Knott
Hassan Mohammed
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404928A external-priority patent/GB2287880A/en
Priority claimed from GB9411842A external-priority patent/GB9411842D0/en
Priority claimed from EP94308493A external-priority patent/EP0654263B1/en
Priority claimed from GB9423498A external-priority patent/GB9423498D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of FI951155A0 publication Critical patent/FI951155A0/fi
Publication of FI951155A publication Critical patent/FI951155A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
FI951155A 1994-03-14 1995-03-13 Farmaseuttinen valmiste FI951155A (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9404928A GB2287880A (en) 1994-03-14 1994-03-14 Production of sustained release compositions
GB9411842A GB9411842D0 (en) 1994-06-14 1994-06-14 Pharmaceutical preparation
EP94308493A EP0654263B1 (en) 1993-11-23 1994-11-17 Method for preparing a sustained release composition
GB9423498A GB9423498D0 (en) 1994-11-21 1994-11-21 Pharmaceutical preparation

Publications (2)

Publication Number Publication Date
FI951155A0 true FI951155A0 (fi) 1995-03-13
FI951155A FI951155A (fi) 1995-09-15

Family

ID=27442925

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951155A FI951155A (fi) 1994-03-14 1995-03-13 Farmaseuttinen valmiste

Country Status (6)

Country Link
EP (1) EP0672416A1 (fi)
JP (1) JPH0840905A (fi)
AU (1) AU694475B2 (fi)
CA (1) CA2144500A1 (fi)
FI (1) FI951155A (fi)
NO (1) NO950950L (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
EP1072257A1 (en) * 1998-04-17 2001-01-31 Taisho Pharmaceutical Co., Ltd Multiple-unit sustained release tablets
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning

Also Published As

Publication number Publication date
CA2144500A1 (en) 1995-09-15
AU694475B2 (en) 1998-07-23
NO950950L (no) 1995-09-15
AU1475595A (en) 1995-09-21
EP0672416A1 (en) 1995-09-20
FI951155A (fi) 1995-09-15
NO950950D0 (no) 1995-03-13
JPH0840905A (ja) 1996-02-13

Similar Documents

Publication Publication Date Title
DK0783302T3 (da) Lægemidler
NO20004345L (no) Farmasøytisk sammensetning
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
BR9507768A (pt) Composição farmacêutica
LV11727A (lv) Farmaceitiska kompozicija
ITMI941169A0 (it) Formulazioni farmaceutiche
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
FI973280A (fi) Farmaseuttinen koostumus
FI951155A0 (fi) Farmaseuttinen valmiste
FI962738A (fi) Farmaseuttiset koostumukset
DE69503368D1 (de) Dermatologisches präparat
BR9605777A (pt) Composição farmacêutica
DE29618094U1 (de) Pharmazeutisches Präparat
NO964309D0 (no) Farmasöytisk sammensetning
SE9402924D0 (sv) Novel pharmaceutical composition
ATA77096A (de) Pharmazeutische präparation
SE9302429D0 (sv) New pharmaceutical preparation ii
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SE9402131D0 (sv) Läkemedel
SE9401674L (sv) Läkemedel
NO944330D0 (no) Legemiddel
SE9404195D0 (sv) New pharmaceutical formulation
NO962816D0 (no) Farmasöytiske forbindelser